Bulletin from Diamyd Medical’s shareholders’ meeting: All of this year’s targets have been met
At Diamyd’s Ordinary General Meeting of Shareholders on December 11, CEO Elisabeth Lindner confirmed that a research team has applied for permission to initiate a prevention study with the Diamyd® vaccine, and that several other independent studies are in the planning stage. However, the spotlight was on the Company's own Phase III studies and its comprehensive repositioning as a market-oriented diabetes company.In addition, the following matters were discussed:The annual meeting of shareholders authorized the board to decide on a new share issue on one or more occasions until the next